eloralintide

A 2025 Phase 2 clinical trial funded by Eli Lilly that enrolled 263 adults who were overweight or obese without diabetes found that once-weekly injectable eloralintide produced dose-dependent weight loss of 9.5% to 20.1% of body weight after 48 weeks, compared with a 0.4% mean weight change in the placebo group.

A 2025 Phase 2 clinical trial of eloralintide reported that treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation in adults who were overweight or obese without diabetes.

A 2025 Phase 2 trial of eloralintide (manufactured by Eli Lilly) in 263 adults with overweight or obesity but without diabetes found that after 48 weeks participants lost between 9.5% and 20.1% of body weight versus 0.4% for placebo, and the treatment was associated with improvements in waist circumference, blood pressure, lipid profiles, glycemic control, and markers of inflammation, with up to 90% of participants improving by at least one BMI category.

In the 2025 Phase 2 trial of eloralintide, the most commonly reported adverse effects were mild-to-moderate gastrointestinal symptoms and fatigue, and these adverse effects were more frequent or severe at higher doses.

Eloralintide is a selective amylin receptor agonist that mimics the pancreatic hormone amylin and is intended to slow gastric emptying, reduce appetite, and help control postprandial blood glucose; this mechanism differs from GLP-1 receptor agonists, which mimic the gut hormone GLP-1.